Researchers led by Université de Montréal pathology and cell-biology professor Marc Therrien have identified major structural ...

A research team has developed a new class of compounds that effectively inhibit both wild-type CDK9 and its drug-resistant ...

Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a ...

The B-cell inhibitors market is experiencing robust growth, driven by the rising prevalence of the addressable patient population, which incl ...

Reviewing the amendment protocol of the AstraZeneca's fixed dose combination (FDC) Zibotentan plus Dapagliflozin, the Subject ...

Bcl6 regulates the lineage stability and suppressive function of Treg cells in head and neck squamous cell carcinoma ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Investigational New ...

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the ...

Patients with vitiligo experience impacts on quality of life, emerging therapies offer promising prospects for more targeted ...

Although the benefit/risk of therapeutic inhibition of VSMC proliferation in atherosclerosis is unclear, experimental and human evidence strongly suggests the therapeutic potential of ...

A 56-year-old man presented for 3 weeks of intermittent blurred vision and photophobia.His medical history included type 2 diabetes, hypertension, hyperlipidemia, chronic obstructive pulmonary disease ...

Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of ...